The latest Business updates from the science industry
by Heather Hobbs Alexandra Knauer Recognised as a Female Entrepreneur Role Model
Alexandra Knauer, Managing Director and owner of the Berlin- based laboratory instrumentation manufacturer Knauer, has been recognised by the jury of the ‘Frauen unternehmen’ initiative (‘Women Entrepreneuring’) to be a role model female entrepreneur. Ms Knauer received a certifi cate signed by the German Federal Minister of Economics and Energy Peter Altmaier.
The initiative ‘Frauen unternehmen’ was launched in 2014 by the German Federal Ministry of Economics and Energy (BMWi) to encourage more women to take the step into self-employment.
From the point of view of the initiative ‘Frauen unternehmen’”, women lack visible role models above all. It is therefore just as important not to perceive women in a leadership role as an exception and to get to know them personally as it is to pass on experience and reduce concerns.
Alexandra Knauer is now one of around 200 experienced female entrepreneurs nationwide who volunteer for the initiative to report on their working life, their motivation and the challenges of running a company. This takes place within the framework of events or visits, which are preferably but not exclusively aimed at young women in the training phase.
The Berlin entrepreneur, who took over the Knauer company from
her parents 20 years ago, has led it very successfully over the years, so that the company has grown to almost double its size in a market dominated by large international competitors.
“I am very pleased to have been chosen by the jury. I will now also gladly share my experiences at the ‘Frauen unternehmen’ events and hope that the Corona crisis will not limit us in this for much longer. I can also imagine digital formats, with which we as a company also have good experiences,” said the newly appointed role model female entrepreneur.
Alexandra Knauer has been committed for many years to the promotion of women in typical male professions, in leadership roles and as entrepreneurs, for example in the district entrepreneurial network ‘Connecting Women’ in Berlin. She also regularly organises the annual ‘Girls’ Day’ in her company, which she sees as an opportunity to give young girls an early insight into her technology company, where many women also work.
Alexandra Knauer attaches great importance to corporate responsibility, not only towards the employees but also towards the environment and society. The subject of ‘Corporate Social Responsibility’ has therefore been a practical part of her company’s work for many years.
Alexandra Knauer is happy to pass on her experience as an entrepreneur to female founders. (Photo: Knauer/Florian Bolk)
More information online:
ilmt.co/PL/ZJD4 52532pr@reply-direct.com
New Company Focused on Candidates for CNS Diseases
Industrial Development (CDTI). The company will develop new drug candidates to treat CNS diseases, supported by a seasoned team with solid pharma and biotech experience which will run operations.
The company is working on three distinct new medicine programs focused on innovative targets (POP, MMP, IGF1). The initial assets, ACT-01 ready for testing in a clinical phase 2 study and both ACT-02 and ACT-03 in preclinical experiments, have been sourced from Spanish R&D companies Bionure and Iproteos and academic research centres with a strong scientifi c background in neurobiology.
“With a portfolio that initially focuses on four CNS disorders – Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy – we are confi dent that Accure will create signifi cant value in a CNS sector with signifi cant market potential and pharma appetite for innovative new medicine programs,” said Montserrat Vendrell, Partner at Alta Life Sciences. “Accure Therapeutics will operate according to the effi cient small R&D pharma model and its team will be best positioned to deliver value to patients, care-givers, doctors and the industry at large.”
Laurent Nguyen
A new pharma R&D player in the Central Nervous System (CNS) fi eld, Accure Therapeutics, has launched with a Series A round of funding totalling €7.6 million ($8.1 million) which was led by Alta Life Sciences and supported by the Centre for Technological and
“We are proud to announce the launch of Accure Therapeutics,” said Laurent Nguyen, founding CEO of Accure Therapeutics. “The high quality assets in our product portfolio have the potential to change the lives of patients living with disabling CNS diseases. Life is a gift, let us work hard to respect it.”
52478pr@reply-direct.com
Distribution
Agreement Marks Start of Global
Self-Testing Business
Medusa19 Limited has entered into a distribution agreement with Avacta Group for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen, originally developed under a partnership agreement between Cytivia (formerly GE Healthcare Life Sciences) and Avacta.
The Group has agreed an exclusive distribution agreement with Medusa19 for the supply of the COVID-19 rapid test direct to consumers globally, subject to the necessary regulatory approvals.
Medusa19 was established by Richard Hughes and Mahmud Kamani, both founder shareholders of
Boohoo.com and shareholders of Avacta1, to build a global consumer self-testing business. Its initial focus will be on COVID-19 home testing and it is currently investing in global e-commerce, logistics and customer support infrastructure in preparation for Avacta’s COVID-19 test launch. Medusa19 will also have non-exclusive rights to supply the tests to businesses for workforce testing. The distribution agreement includes a profi t- sharing arrangement.
The global demand for rapid antigen tests, which will be critical to lockdown exit strategies around the world in order to get healthy, non-contagious people back to work, could be many millions of tests per month. There will also be an ongoing need for several years for this type of testing as the disease recurs.
52476pr@reply-direct.com
To be included in our next issue, send all your News stories to:
heather@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
